<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have recently described a method for radiolabeling monoclonal antibodies, with metallic radionuclides using a new chelating agent N2S3 </plain></SENT>
<SENT sid="1" pm="."><plain>Using this chelate the monoclonal antibodies Lym-1 and B72.3 were labeled with 186Re and their biological integrity was evaluated in vitro and in vivo </plain></SENT>
<SENT sid="2" pm="."><plain>186Re-labeled antibodies using N2S4 methodology were found to be stable in human serum and retained their immunoreactivity </plain></SENT>
<SENT sid="3" pm="."><plain>Intravenous administration of 0.5 mCi 186Re-labeled antibodies resulted in partial or complete regression of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue in mice </plain></SENT>
</text></document>